JP2013530702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530702A5 JP2013530702A5 JP2013515873A JP2013515873A JP2013530702A5 JP 2013530702 A5 JP2013530702 A5 JP 2013530702A5 JP 2013515873 A JP2013515873 A JP 2013515873A JP 2013515873 A JP2013515873 A JP 2013515873A JP 2013530702 A5 JP2013530702 A5 JP 2013530702A5
- Authority
- JP
- Japan
- Prior art keywords
- human insulin
- desb30
- insulin
- amino acid
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 78
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 72
- 102200127556 rs34159654 Human genes 0.000 claims 58
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 43
- 239000004026 insulin derivative Substances 0.000 claims 34
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 31
- 235000018417 cysteine Nutrition 0.000 claims 26
- 102220092852 rs754853086 Human genes 0.000 claims 23
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 22
- 125000000539 amino acid group Chemical group 0.000 claims 15
- 235000001014 amino acid Nutrition 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 3
- -1 cysteine amino acid Chemical class 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102000003746 Insulin Receptor Human genes 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 238000002741 site-directed mutagenesis Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10167033 | 2010-06-23 | ||
| EP10167033.9 | 2010-06-23 | ||
| US35950010P | 2010-06-29 | 2010-06-29 | |
| US61/359,500 | 2010-06-29 | ||
| PCT/EP2011/060382 WO2011161124A1 (en) | 2010-06-23 | 2011-06-21 | Insulin analogues containing additional disulfide bonds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530702A JP2013530702A (ja) | 2013-08-01 |
| JP2013530702A5 true JP2013530702A5 (OSRAM) | 2014-07-31 |
| JP5973427B2 JP5973427B2 (ja) | 2016-08-23 |
Family
ID=43242459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013515873A Expired - Fee Related JP5973427B2 (ja) | 2010-06-23 | 2011-06-21 | 追加のジスルフィド結合を含有するインスリン類似体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8815798B2 (OSRAM) |
| EP (1) | EP2585484A1 (OSRAM) |
| JP (1) | JP5973427B2 (OSRAM) |
| CN (1) | CN102947331B (OSRAM) |
| WO (1) | WO2011161124A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| CN104693302A (zh) | 2010-06-23 | 2015-06-10 | 诺沃—诺迪斯克有限公司 | 包含额外的二硫键的胰岛素衍生物 |
| EP2686003A2 (en) * | 2011-03-15 | 2014-01-22 | Novo Nordisk A/S | Human insulin analogues and derivatives comprising cysteine substitutions |
| JP2015502971A (ja) * | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー/エス | N末端修飾インスリン誘導体 |
| KR20160065126A (ko) | 2013-10-07 | 2016-06-08 | 노보 노르디스크 에이/에스 | 인슐린 유사체의 신규한 유도체 |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| ES2908373T3 (es) | 2015-08-25 | 2022-04-28 | Novo Nordisk As | Nuevos derivados de insulina y los usos médicos de los mismos |
| KR20180097517A (ko) * | 2015-12-23 | 2018-08-31 | 케이스 웨스턴 리저브 유니버시티 | 매우 안정된 인슐린 유사체의 중합체 용융물 내 캡슐화 |
| AU2017378102B2 (en) | 2016-12-16 | 2022-10-13 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| CN111032685A (zh) | 2017-08-17 | 2020-04-17 | 诺沃挪第克公司 | 新型酰化胰岛素类似物及其用途 |
| PE20221260A1 (es) | 2019-12-11 | 2022-08-16 | Novo Nordisk As | Analogos de insulina novedosos y usos de estos |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE50892B1 (en) | 1980-02-11 | 1986-08-06 | Novo Industri As | Process for preparing insulin esters |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| DK105489D0 (da) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| ZA954983B (en) | 1994-06-17 | 1996-02-14 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| RU2283846C2 (ru) | 1999-12-29 | 2006-09-20 | Ново Нордиск А/С | Предшественник инсулина, способ его получения и применение |
| AU2003903124A0 (en) * | 2003-06-20 | 2003-07-10 | Mark Del Borgo | Analogues of heteromeric proteins |
| JP4463814B2 (ja) | 2003-08-05 | 2010-05-19 | ノボ ノルディスク アクティーゼルスカブ | 新規のインスリン誘導体 |
| JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー/エス | 単鎖インシュリン |
| WO2007096332A1 (en) | 2006-02-21 | 2007-08-30 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| WO2007135117A2 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
| RU2524150C2 (ru) | 2006-09-22 | 2014-07-27 | Ново Нордиск А/С | Аналоги инсулина, устойчивые к протеазам |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| ES2618073T3 (es) * | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| EP2376531A1 (en) * | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Novel insulin analogues |
| US20120184488A1 (en) * | 2009-09-01 | 2012-07-19 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
-
2011
- 2011-06-21 CN CN201180030864.2A patent/CN102947331B/zh not_active Expired - Fee Related
- 2011-06-21 JP JP2013515873A patent/JP5973427B2/ja not_active Expired - Fee Related
- 2011-06-21 US US13/805,503 patent/US8815798B2/en not_active Expired - Fee Related
- 2011-06-21 WO PCT/EP2011/060382 patent/WO2011161124A1/en not_active Ceased
- 2011-06-21 EP EP11728614.6A patent/EP2585484A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530702A5 (OSRAM) | ||
| JP2013530974A5 (OSRAM) | ||
| JP2014129355A5 (OSRAM) | ||
| KR102092025B1 (ko) | 페길화된 옥신토모둘린 변이체 | |
| DK2727605T3 (en) | EXENDIN-4 ANALOG PEGYLED WITH POLYETHYLENE LYCOL OR A DERIVATIVE THEREOF, PROCEDURE FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DIABLE SUBSTANCES, | |
| TR201815158T4 (tr) | Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri. | |
| JP2013532970A5 (OSRAM) | ||
| RU2012157683A (ru) | Производные инсулина, содержащие дополнительные дисульфидные связи | |
| US20170088598A1 (en) | Long-acting oxyntomodulin variants and methods of producing same | |
| RU2013145013A (ru) | Новые аналоги глюкагона | |
| JP2012506402A5 (OSRAM) | ||
| JP2011526886A5 (OSRAM) | ||
| JP2014520798A5 (OSRAM) | ||
| JP2013518090A5 (OSRAM) | ||
| JP2013517307A5 (OSRAM) | ||
| JP2013533227A5 (OSRAM) | ||
| JP2018506507A5 (OSRAM) | ||
| JP2022095872A (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| JP2015513544A5 (OSRAM) | ||
| JP2013515055A5 (OSRAM) | ||
| JP2011241213A5 (OSRAM) | ||
| JP2018505146A5 (OSRAM) | ||
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| JP2012511506A5 (OSRAM) |